Solvay Pharmaceuticals will evaluate all options for the future of the compound
Solvay Pharmaceuticals acknowledges Wyeth Pharmaceuticals’ announcement earlier today to terminate the collaboration agreement on bifeprunox and two early stage compounds (SLV313 and SLV314). The agreement signed in 2004 allowed for the co-development and co-commercialization of the three compounds.
“Solvay of course respects Wyeth’s decision. This successful collaboration brought the compounds to their current stage of development” said Dr Claus Steinborn, Executive Vice President Global R&D of Solvay Pharmaceuticals. “We will add the compounds again to Solvay’s portfolio and analyze all options.”
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfil carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology, and men’s and women’s health. Its 2007 sales were EUR 2.6 billion and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at www.solvay.com
